Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
loxapine
loxapine
Cell Status
NFISA
Brand names:
Loxapine Succinate, LOXITANE
Form
Strength
CAPSULE, ORAL
10 mg; 25 mg; 50 mg
Additional Information:
JANUARY 2011 P&T MINUTES
Last updated:
Jan. 24, 2018
Black Box Warning:
Elderly patients with dementia related psychosis
Black Box Warning:
Aerosol: Bronchospasm
FDA Drug Safety:
Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
JANUARY 2011 P&T MINUTES